Login to Your Account



Chasing Mipomersen

Karo Bio Moves Eprotirome to Pivotal HeFH Trial; MAA in 2014?

By Cormac Sheridan


Wednesday, September 21, 2011
Next month, Karo Bio AB will begin recruitment in a pivotal Phase III trial of eprotirome in patients with heterozygous familial hypercholesterolemia (HeFH), having received a green light from regulatory authorities in Europe. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription